Revvity (RVTY) stock
Health Care · Health Care Equipment
Revvity (RVTY) is a Health Care Equipment company in the Health Care sector, headquartered in Waltham, Massachusetts. As of October 23, 2026, RVTY closed at $158.77, a market capitalization of $17.72 billion, the 425th largest company in the S&P 500. The stock trades at 76.0x trailing earnings and 26.9x forward earnings.
- 1-year total return: +63.1% (dividends reinvested)
- 5-year return: -1.8% a year
- 52-week range: $81.22 – $166.25
- Dividend yield: 0.18%
- FI Handbook report card: B- across 5 metrics
- 50th largest of 60 Health Care stocks in the S&P 500
RVTY price chart
1Y price change: +62.7% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| RVTY | +11.8% | +64.5% | +63.1% | +16.1% | -1.8% | +12.0% | +11.3% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1973.
RVTY key statistics
- Market cap
- $17.7B
- #425 in S&P 500
- P/E (TTM)
- 76.0x
- Forward P/E
- 26.9x
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Free cash flow
- $558.1M
- Gross margin
- —
- Operating margin
- —
- Return on equity
- —
- Dividend yield
- 0.18%
- 52-week range
- $81.22 – $166.25
- Beta
- —
- Price / sales
- —
- EV / EBITDA
- —
- Debt / equity
- —
- Employees
- —
RVTY report card
B-Ten fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth——
- Gross margin——
- Operating margin——
- FCF margin——
- Return on equity——
- Net debt / EBITDA0.0xA
- Forward P/E26.9xC
- PEG ratio0.7xA
- Shareholder yield4.8%B
- Share count change / yr0.9%D
Revvity financials
Revenue went from $2.2B in fiscal 2014 to $2.9B in fiscal 2025, growing 2.2% a year.
| Fiscal year | 2014 | 2016 | 2017 | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2B | $2.1B | $2.3B | $2.8B | $2.9B | $2.7B | $3.8B | $2.8B | $2.8B | $2.9B |
| Gross profit | $1.0B | $964.2M | $1.1B | $1.3B | $1.4B | $2.1B | $2.4B | — | — | — |
| Operating income | $165.0M | $250.9M | $295.6M | $323.9M | $362.0M | $867.3M | $1.3B | $300.6M | $346.7M | $356.6M |
| Net income | $157.8M | $212.4M | $292.6M | $237.9M | $227.6M | $727.9M | $943.2M | $693.1M | $270.4M | $241.2M |
| EPS (diluted) | $1.39 | $1.87 | $2.64 | $2.13 | $2.04 | $6.49 | $8.08 | $5.55 | $2.20 | $2.07 |
| Free cash flow | $254.4M | $258.9M | $249.4M | $217.8M | $287.1M | $828.5M | $1.3B | $9.9M | $541.7M | $509.4M |
| Buybacks | $65.5M | $76.4M | $3.8M | $57.4M | $6.3M | $6.9M | $73.1M | $388.9M | $369.6M | $820.8M |
| Dividends paid | $31.6M | $31.6M | $30.8M | $31.0M | $31.1M | $31.2M | $32.4M | $35.0M | $34.5M | $32.8M |
| Diluted shares | 113.7M | 113.3M | 110.9M | 111.5M | 111.5M | 112.1M | 116.7M | 124.8M | 122.8M | 116.6M |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into RVTY?
A reverse DCF asks what growth the current price requires. With an enterprise value of $17.7B and $558.1M of trailing free cash flow, Revvity needs to grow free cash flow about 22.4% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew 12.1% a year over the last five years.
P/E ratio history
Current 76.7x vs. median 30.4x (10th–90th percentile 9.7x–53.7x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
RVTY dividend
- Dividend yield
- 0.18%
- Annual dividend
- $0.28
- Years of increases
- —
- 5-yr dividend growth
- 0.0%
- per year
- Payments per year
- 4
Regular dividends per share by calendar year; special dividends excluded. Current year omitted until complete.
RVTY analyst price targets
18 analysts' average 12-month target is $147.53 (-7% vs. $158.77). Targets range from $110.00 to $175.00. 33% rate it a buy.
RVTY earnings
Next report: November 3, 2026. Revvity has beaten EPS estimates 8 quarters in a row. Last quarter's revenue was $729.7M (+1% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Aug 4, 2026 | $1.22 | $1.41 | +15.9% |
| May 5, 2026 | $1.01 | $1.06 | +4.5% |
| Feb 2, 2026 | $1.58 | $1.70 | +7.8% |
| Oct 27, 2025 | $1.14 | $1.18 | +3.6% |
| Jul 28, 2025 | $1.14 | $1.18 | +3.4% |
| Apr 28, 2025 | $0.95 | $1.01 | +6.4% |
| Jan 31, 2025 | $1.38 | $1.42 | +3.1% |
| Nov 4, 2024 | $1.13 | $1.28 | +13.6% |
Stocks like RVTY
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 ABT Abbott Laboratories | +1.16% | -16% | $179.4B | 38.6x | Compare |
 ISRG Intuitive Surgical | +1.90% | -18% | $159.8B | 54.7x | Compare |
 MDT Medtronic plc. | -1.22% | +5% | $122.0B | 23.4x | Compare |
 SYK Stryker | +0.02% | -19% | $117.8B | 31.8x | Compare |
 BSX Boston Scientific | -0.70% | -55% | $66.2B | 18.5x | Compare |
 BDX Becton, Dickinson and | -0.75% | +39% | $54.2B | 46.3x | Compare |
 EW Edwards Lifesciences Corporatio | -1.13% | +16% | $51.3B | 53.0x | Compare |
 IDXX IDEXX Laboratories | -1.13% | -12% | $44.1B | 39.4x | Compare |
RVTY news
- ELV vs. RVTY: Which Stock Is the Better Value Option? · Oct 23, 2026
- Revvity Launches Signals LabGistics to Coordinate Scientific Workflows · Oct 22, 2026
- Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows · Oct 20, 2026
- 1 Cash-Producing Stock to Own for Decades and 2 We Question · Oct 16, 2026
- Revvity (RVTY), What Is Drawing Fresh Attention Now? · Oct 15, 2026
RVTY stock FAQ
What is RVTY's market cap?
Revvity's market capitalization is $17.72 billion as of October 23, 2026, ranking 425th in the S&P 500.
What is RVTY's P/E ratio?
RVTY trades at a trailing price-to-earnings ratio of 76.0x and a forward P/E of 26.9x. Its median P/E over the period we track is 30.4x.
Does RVTY pay a dividend?
Yes. Revvity pays $0.28 per share a year, a 0.18% yield. Dividends grew 0.0% a year over the last five years.
How much has RVTY stock returned?
Including reinvested dividends, RVTY returned +63.1% over one year, -1.8% a year over five years, +12.0% a year over ten years through October 23, 2026.
Is RVTY stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Revvity must grow free cash flow about 22% a year for the next decade. Its free cash flow grew 12% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
What is the RVTY price target?
18 analysts cover RVTY with an average 12-month price target of $147.53, -7% from the current price. 33% of them rate it a buy.
When does RVTY report earnings?
Revvity is expected to report earnings on November 3, 2026. It has beaten EPS estimates 8 quarters in a row.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology